Last10K.com

Oncotelic Therapeutics, Inc. (OTLC) SEC Filing 10-Q Quarterly Report for the period ending Wednesday, March 31, 2021

Oncotelic Therapeutics, Inc.

HISTORY TOOLS
CIK: 908259 Ticker: OTLC
Document and Entity Information - shares
3 Months Ended
Mar. 31, 2021
May 20, 2021
Cover [Abstract]  
Entity Registrant NameOncotelic Therapeutics, Inc. 
Entity Central Index Key0000908259 
Document Type10-Q 
Document Period End DateMar. 31, 2021 
Amendment Flagfalse 
Current Fiscal Year End Date--12-31 
Entity Current Reporting StatusYes 
Entity Interactive Data CurrentYes 
Entity Filer CategoryNon-accelerated Filer 
Entity Small Business Flagtrue 
Entity Emerging Growth Companyfalse 
Entity Shell Companyfalse 
Entity Common Stock, Shares Outstanding 369,696,959
Document Fiscal Period FocusQ1 
Document Fiscal Year Focus2021 

View differences made from one quarter to another to evaluate Oncotelic Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Oncotelic Therapeutics, Inc..

Continue

Assess how Oncotelic Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Oncotelic Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Consolidated Balance Sheets (Unaudited)
Consolidated Balance Sheets (Unaudited) (Parenthetical)
Consolidated Statement Of Stockholders' Equity (Unaudited)
Consolidated Statements Of Cash Flows (Unaudited)
Consolidated Statements Of Operations (Unaudited)
Accounts Payable And Accrued Expenses
Accounts Payable And Accrued Expenses (Tables)
Accounts Payable And Accrued Expenses - Schedule Of Accounts Payable And Accrued Expenses (Details)
Commitments And Contingencies
Commitments And Contingencies (Details Narrative)
Convertible Debentures, Notes And Other Debt
Convertible Debentures, Notes And Other Debt (Details Narrative)
Convertible Debentures, Notes And Other Debt - Schedule Of Convertible Debentures (Details)
Convertible Debentures, Notes And Other Debt - Schedule Of Convertible Debentures (Details) (Parenthetical)
Convertible Debentures. Notes And Other Debt (Tables)
Description Of Business And Basis Of Presentation
Description Of Business And Basis Of Presentation (Details Narrative)
Income Taxes
Income Taxes (Details Narrative)
Income Taxes (Tables)
Income Taxes - Schedule Of Components Of Net Deferred Tax Assets And Liabilities (Details)
Intangible Assets And Goodwill
Intangible Assets And Goodwill (Details Narrative)
Intangible Assets And Goodwill (Tables)
Intangible Assets And Goodwill - Schedule Of Amortization Of Expense For Intangible Assets (Details)
Intangible Assets And Goodwill - Schedule Of Intangible Assets (Details)
Private Placement And Jh Darbie Financing
Private Placement And Jh Darbie Financing (Details Narrative)
Private Placement And Jh Darbie Financing (Tables)
Private Placement And Jh Darbie Financing - Schedule Of Fair Value Warrants Estimated Using Black Scholes Valuation Model (Details)
Private Placement And Jh Darbie Financing - Schedule Of Funds Received Under The Subscription Agreement (Details)
Related Party Transactions
Related Party Transactions (Details Narrative)
Stock-Based Compensation
Stock-Based Compensation (Details Narrative)
Stock-Based Compensation (Tables)
Stock-Based Compensation - Schedule Of Black Scholes Valuation Allowance Model Of Warrants (Details)
Stock-Based Compensation - Schedule Of Compensation Based Stock Option Activity (Details)
Stock-Based Compensation - Schedule Of Options To Purchase Shares Of Common Stock Outstanding And Exercisable (Details)
Stock-Based Compensation - Schedule Of Warrants Activity (Details)
Stock-Based Compensation - Schedule Of Warrants Outstanding And Exercisable (Details)
Stockholders' Equity
Stockholders' Equity (Details Narrative)
Subsequent Events
Subsequent Events (Details Narrative)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Details Narrative)
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Summary Of Significant Accounting Policies - Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share (Details)
Summary Of Significant Accounting Policies - Summary Of Changes In Fair Value Of Derivative Liabilities (Details)
Summary Of Significant Accounting Policies - Summary Of Estimate Fair Value Of Derivative Liabilities (Details)

Material Contracts, Statements, Certifications & more

Oncotelic Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 32.1: Section 1350 Certification
Exhibit 32.2: Section 1350 Certification
Ticker: OTLC
CIK: 908259
Form Type: 10-Q Quarterly Report
Accession Number: 0001493152-21-012700
Submitted to the SEC: Mon May 24 2021 4:16:30 PM EST
Accepted by the SEC: Mon May 24 2021
Period: Wednesday, March 31, 2021
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/otlc/0001493152-21-012700.htm